Prospective, open-label evaluation of a new albuterol multidose dry powder inhaler with integrated dose counter

Abstract

NCT01857323.

The pharmacokinetics, safety, and tolerability of single, high-strength doses of fluticasone propionate and fluticasone propionate/salmeterol delivered via a novel multidose dry powder inhaler in adolescents and adults with persistent asthma

“…Poor inhaler technique, sometimes stemming from an inability to coordinate inhalation with actuation, has the potential to lead to poor patient outcomes (21). A recent article evaluated patient satisfaction and ease of use of albuterol delivered using an MDPI delivery device similar to that used in the present study (13). Greater than 90% of patients ࣙ4 years of age with asthma or chronic obstructive disease responded that they were "very satisfied, " "satisfied, " or "somewhat satisfied" when asked about the ease of use in handling and holding the inhaler, in using the inhaler, and in inhaling a dose from the MDPI (13).…”

“…A novel, inhalation-driven, multidose dry powder inhaler (MDPI; Teva Pharmaceutical Industries, Frazer, PA, USA) was developed that is intuitive and simple for patients to use (13). The MDPI does not require the patient to coordinate actuation and inhalation and has increased the efficiency of dose delivery compared with a conventional dry powder inhaler (DPI) (9,14).…”

Novel albuterol multidose dry powder inhaler in patients with exercise-induced bronchoconstriction: A single-dose, double-blind, randomized, 2-way crossover study

“…Devices that use breath actuation have been found to reduce administration errors compared with conventional MDIs [8]. In a recent study conducted in 317 patients with asthma or chronic obstructive pulmonary disease, ease-of-use and patient satisfaction with the albuterol MDPI were assessed using a questionnaire in which responses were rated on a 7-point scale [15]. The majority (83%) of patients were somewhat to very satisfied with the albuterol MDPI inhaler.…”

Dry Powder Inhalers—Between the Doctor and the Patient

“…In the past few years some new passive DPI have entered the market (in order of appearing in the market): NEXThaler ® , Ellipta ® , Forspiro ® or Zonda ® [15][16][17][18]. The new devices usually generate aerosols which have better parameters, normally practically independent from the patient's inspiratory flow but concurrently more patient-friendly in the everyday use compared with the previously appllied devices [19][20][21]. Ellipta ® is a good example of such an inhaler.…”